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Although small-cell lung cancer (SCLC) makes up a smaller pro-
portion of all lung cancers than it did 25 years ago, it remains a
common cause of cancer mortality that requires more clinical and
basic research than is currently underway. Trials of newer chemo-
therapy variations have failed to produce a regimen that is clearly
superior to the two-drug combination of etoposide and cisplatin,
which remains the standard of care for both limited and extensive
stage SCLC. Paradoxically, advances in this systemic disease have
come from radiotherapy innovations for limited SCLC, including
addition of thoracic irradiation to systemic chemotherapy, more
intense thoracic irradiation, early integration of thoracic irradiation
with systemic chemotherapy, and prophylactic cranial irradiation.
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In the 1970s, small-cell lung cancer (SCLC) was estimatedto account for 20 to 25% of all lung cancers.1 At the height
of the lung cancer epidemic for male patients in 1986, an
analysis of the Surveillance, Epidemiology and End Results
database showed that the actual proportion of SCLC cases
was 17.2%.2 The percentage continued downward to 13.8%
of all lung cancers in North America by 1998. This declining
incidence of SCLC parallels a stalling in the pace of inves-
tigation, as reflected by the number of abstracts submitted to
the American Society of Clinical Oncology over the past 25
years (Figure 1). In contrast, the number of abstracts for
non–small cell lung cancer (NSCLC) has skyrocketed. The
slow pace of SCLC investigation is unfortunate and puzzling
because the proportion of estimated deaths from this disease
is approximately 4% of all cancer mortality.3 The number of
patients dying as a result of SCLC is similar to that of ovarian
cancer, leukemia, and non-Hodgkin’s lymphoma, all of
which have robust investigational agendas.
THE IMPORTANCE OF STAGING
Accurate staging determines the intent and structure of
the treatment program. Although there is no worldwide
agreement and the origins are rooted in studies from another
generation, the Veterans Administration Lung Group system4
is most widely used in North America. That staging system,
which divided patients into either limited or extensive stages,
has been durable for SCLC because of its simplicity and
reliable prognostic value. Limited-stage SCLC (LSCLC) is
defined as tumor confined to one hemithorax and the regional
lymph nodes, whereas extensive-stage small cell lung cancer
(ESCLC) is defined as disease beyond these bounds. The
original operational definition of limited disease was tumor
quantity and configuration that could be encompassed by a
“reasonable” radiotherapy treatment volume. Because long-
term survival is uncommon (5–7%) when chemotherapy
alone is used to treat LSCLC,5 the “reasonable radiotherapy
port” rule continues to be of practical importance in the
assembly of combined-modality therapy programs that in-
crease the long-term survival rate to over 20%. SCLC typi-
cally spreads early, with 60 to 70% of patients having ESCLC
with metastases outside the limited-stage definition. Although
patients with “regional” extensive stage disease such as
pleural effusions and contralateral hilar and supraclavicular
nodes may be given combined-modality therapy with a small
chance of cure, ESCLC is typically treated with palliative
intent. In addition to limited stage, other pretreatment prog-
nostic factors associated with a favorable outcome in Cox
regression analyses include good performance status, a low
alkaline phosphatase level, a normal lactate dehydrogenase,
and female gender.6–8 Many have argued that the use of the
TNM system used by the American Joint Committee on
Cancer and the International Union Against Cancer delivers
consistency with other disease sites and NSCLC. The Inter-
national Association for the Study of Lung Cancer staging
committee will make recommendations in the upcoming year
to address these issues based on worldwide databases. What
influence positron emission tomographic scanning has on
staging and treatment will not be addressed for some years
because of a paucity of data in SCLC.
The natural history of untreated SCLC is dismal, with a
median survival of only 2 months for ESCLC and 3 months
for LSCLC.4 Over 40 years ago, it was recognized that SCLC
was more responsive than NSCLC to both ionizing radiation
and many cytotoxic drugs.4,9 However, after decades of
clinical research, SCLC has proved less tractable than most
thought it would. It has become clear that despite higher
response rates and some complete responses to combination
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chemotherapy, the survival outcome for ESCLC is similar to
metastatic NSCLC. Moreover, the median survival and the
proportion of long-term survivors of patients treated with
chemoradiation for LSCLC and stage III NSCLC are approx-
imately the same.10,11 The time required for treatment-resis-
tant clones to cause a fatal outcome is similar for SCLC and
NSCLC. Both are virulent epithelial neoplasms that respond
somewhat to radiotherapy and chemotherapy.
STANDARD CHEMOTHERAPY REGIMENS FOR
SCLC
A major step in the systemic treatment of SCLC was
reported in 1969, when alkylating agents were compared to
an inert compound in approximately 2000 lung cancer pa-
tients at a group of Veterans Administration Hospitals.4
Antitumor effects of chemotherapy were analyzed according
to cell type, and improvement in survival was the sole
criterion of drug activity. Although the 4-month median
survival for SCLC patients was only slightly better than the
1.5-month median survival of inert compound–treated pa-
tients (p  0.0005), the trial was the first to show a statisti-
cally significant survival benefit of chemotherapy in lung
cancer. Cyclophosphamide became a cornerstone in success-
ful SCLC treatment, as was nitrogen mustard in the MOPP
regimen (mechlorethamine, Oncovin [vincristine], procarba-
zine, and prednisone) in treatment of Hodgkin’s disease.
Although the magic combination never emerged, the
power of chemotherapy was clearly improved with mul-
tiagent chemotherapy. Many permutations and variations of
protocols containing five drugs (cyclophosphamide, doxoru-
bicin, vincristine, etoposide, and cisplatin) or their analogues
have been reported and a number of regimens have been used
in phase III studies. In 1975, Einhorn and colleagues12 com-
bined cyclophosphamide, doxorubicin, and vincristine
(CAV); not only were high response rates produced but
complete responses were observed in 20% of cases. It is
notable and somewhat disconcerting that the CAV regimen
and cyclophosphamide, doxorubicin, and etoposide (CAE)
have persisted as standard combinations for 30 years. Interest
in the combination of etoposide and cisplatin (EP)13 was
stimulated after it was shown to produce tumor regression in
patients whose cancers had progressed following initial drug
treatment with a cyclophosphamide-based regimen.14 The
consistent performance of EP or carboplatin and etoposide in
clinical trials plus the bonus of its compatibility with radio-
therapy has made it a standard of such durability that it
persists as the treatment of choice.15
INVESTIGATIONAL CHEMOTHERAPY FOR
EXTENSIVE STAGE SCLC
Extensive stage SCLC remains impervious to chemo-
therapy innovations. At the most basic level, it was easily
demonstrated that monotherapy is inferior to combination
chemotherapy.16,17 However, beyond that, it has not been
shown conclusively that any innovation of chemotherapy has
been associated with a consistent improvement in survival.
Major areas of research have been chemotherapy diversity,
quantity of drugs administered (dose, dose intensity, duration
of chemotherapy), and introduction of new agents. New drug
development has included testing in previously untreated
extensive disease patients without apparent detriment to sur-
vival, but others point out that the need is for agents that
cause response in disease resistant to standard therapy. Un-
fortunately, no such agents loom on the horizon.
Drug diversity is a fundamental principle governing the
use of combination chemotherapy that attempts to avoid or
minimize the development of resistant clones.18 Models of
drug diversity acquisition include the following: standard
regimen with drug addition, drug substitution studies, alter-
nating combinations, and complex weekly regimens. An
informative study by the Southeastern Cancer Study Group
that compared sequential CAV (cyclophosphamide, doxoru-
bicin [Adriamycin], and vincristine [Oncovin]), sequential EP
(etoposide and cisplatinum), and alternating CAV/EP showed
no differences in response rates or survival for ESCLC.19 In
addition, this trial demonstrated that an isoeffective result
could be generated with four cycles of EP compared with six
cycles of CAV or CAV/EP. The CODE (cisplatin, vincristine,
doxorubicin, and etoposide) regimen incorporated both drug
diversity and a doubling of dose intensity but failed to
improve survival for ESCLC when compared with CAV/
EP.20
Occasional examples exist of an incremental but statis-
tically significant benefit of adding a third drug to a two-drug
protocol in ESCLC such as ifosfamide to the EP regimen,21
but the small size of the survival gain and the toxicity/
logistical cost have not changed practice. Other drug addition
studies such as comparing the addition of paclitaxel and
granulocyte colony-stimulating factor to EP (TEP) versus EP
have clearly had no impact on survival in ESCLC.22 The
addition of paclitaxel to EP did result in added toxicity. Renal
toxicity, motor-sensory neuropathy, and hearing loss were
more common in the TEP arm. The toxic death rate was three
times as common in patients receiving the triplet combination
FIGURE 1. Numbers of abstracts published for American
Society of Clinical Oncology annual meetings between 1980
and 2006 for (1) all lung cancer; (2) non-small-cell lung can-
cer; (3) small-cell lung cancer.
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(6.5% versus 2.4%). The Greek Lung Cancer Cooperative
Group also conducted a prospective randomized trial of TEP
versus EP.23 The trial was closed early because of unaccept-
able toxicity in the three-drug arm.
In a different type of drug addition study, the Eastern
Cooperative Oncology Group randomized ESCLC patients
that were stable or responding to four induction courses of EP
to four cycles of maintenance or consolidation chemotherapy
with topotecan or a control group.24 Progression-free survival
was trivially better for the topotecan arm than for the obser-
vation arm (3.6 versus 2.3 months). However, there was no
difference in median survival (8.9 versus 9.3 months; p 
0.43), and topotecan added substantial toxicity. In this study,
it is poignant that even when ESCLC patients are selected for
chemoresponsive biology (patients with progressive disease
were not randomized), maintenance treatment beyond four
cycles of EP with putatively non–cross-resistant properties
failed to improve survival.
Meta-analysis of dose intensity25 and randomized tri-
als26–29 of dose intensification have consistently been nega-
tive in ESCLC. Although trials of high-dose chemotherapy
with stem-cell support for SCLC are still underway in Eu-
rope, the failure of this approach to overcome drug resistance
in epithelial cancers in general has marginalized this difficult
line of investigation to enthusiasts.
With respect to the introduction of new chemotherapy
agents, a phase III trial from Japan30 was stopped early when
the combination or irinotecan and cisplatin demonstrated
survival superiority to the EP combination in ESCLC. Me-
dian survival was typical in the EP arm at 9.4 months versus
12.8 months for the irinotecan-treated arm (p  0.002). At 2
years, the percentage of patients surviving was 19.5% versus
5.2%. At the 2005 meeting of the American Society of
Clinical Oncology, a phase III trial of a different schedule
(days 1 and 8) of irinotecan and cisplatin generated identical
outcomes compared to the EP regimen.31 A confirmatory
phase III trial by the Southwest Oncology Group (S0124) is
designed to reproduce the clinical data of the Japanese trial in
a larger population (620 patients) and also investigate phar-
macogenomic endpoints predictive of toxicity or efficacy of
irinotecan and cisplatin. In addition, this study will examine
polymorphisms of genes associated with drug metabolism
(UGT1A1) and excision repair genes for platinum (ERCC-1,
XRCC-1). In the largest phase III trial ever conducted for
SCLC, Eckardt et al.32 randomized 859 patients to EP versus
cisplatin with oral topotecan. Response rates, median time to
progression, and overall survival were not different. The
negative results of the two North American trials31,32 testing
the utility of the substitution of topoisomerase I inhibitors for
etoposide in a platinum protocol have generated a pall of
pessimism that combinations with this drug class are capable
of displacing EP as standard therapy for ESCLC.
Other new drugs such as pemetrexed33 and amrubicin34
are active and undergoing testing in combination with a
platinum agent in ESCLC. However, like advanced NSCLC,
it is increasingly unlikely that the plateau in the power of
treatment for ESCLC will be changed with the introduction of
new cytotoxic agents.
IMPACT OF CHEMOTHERAPY INNOVATIONS
FOR LSCLC
Although chemotherapy alone cures a small proportion
of LSCLC,5 long-term survivors in the ESCLC population are
uncommon (1%). This difference makes LSCLC a model of
a curable neoplasm where incremental improvements in che-
motherapy efficacy can be more easily detected than in
palliative ESCLC patients. This effect has been shown in
several clinical trials using a variety of chemotherapy varia-
tions.
The most notable example comes from Norway, where
Sundstrom et al.35 randomized 436 patients with SCLC to
either cyclophosphamide, epirubicin, and vincristine or EP
for five cycles; 218 limited stage patients were to receive
thoracic irradiation between the third and fourth course of
chemotherapy to a dose of 42 Gy. For ESCLC patients, there
was no significant survival difference between the treatment
arms. However, for LSCLC, the median survival time was
14.5 months versus 9.7 months in the EP and CEV arms,
respectively (p  0.001). The 2- and 5-year survival rates of
25% and 19%, respectively, in the EP arm compared with 8%
and 3% in the CEV arm (p  0.001). This trial provides
compelling evidence that cyclophosphamide/anthracycline
regimens are inappropriate first-line regimens for LSCLC.
In a drug substitution trial, Reck et al.36 compared
carboplatin, etoposide, and vincristine (CEV) to paclitaxel,
etoposide, and carboplatin (TEC)—the experimental arm.
The 608-patient study included 302 patients with LSCLC,
and randomization was stratified by stage. LSCLC patients
received thoracic irradiation after six cycles of chemotherapy.
Median survival for patients in the TEC arm was superior to
that achieved by patients in the CEV arm (12.7 versus 11.7
months), and the hazard ratio of death was statistically sig-
nificantly higher for patients in the CEV arm (hazard ratio,
1.22; p 0.02). When analyzed by stage, the median survival
advantage of TEC over CEV was confined to LSCLC patients
(17.6 versus 16.6 months); the difference in 3-year survival
appears more impressive but was not cited in the article.
There was no difference in outcome for ESCLC, where the
median survival was 9.8 versus 10.0 months.
In a trial of dose intensification, Thatcher et al.37
randomized 403 patients to a standard six cycles of doxoru-
bicin, cyclophosphamide, and etoposide (ACE) at 3-week
intervals versus the same regimen given every 2 weeks with
granulocyte colony-stimulating factor support. The patient
population had predominant limited stage disease (77%), and
all patients had good prognostic factors as defined by this
group. Survival was longer in the intensified group (hazard
ratio, 0.80; 95% confidence interval, 0.65–0.99; p  0.04).
At 24 months, survival was 13% versus 8% in favor of the
more intensive regimen. The same group examined a patient
population with a higher proportion of LSCLC patients (87%)
and favorable prognostic factors with a randomization be-
tween ifosfamide, carboplatin, etoposide, and vincristine
(ICE-V) versus standard chemotherapy (mainly cyclophos-
phamide, doxorubicin, and vincristine).38 Consolidation tho-
racic irradiation and prophylactic cranial irradiation was rec-
ommended after chemotherapy was complete. The median
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survival was 15.6 months in the ICE-V group and 11.6
months in the control group, and the 2-year survival rates
were 20% and 11%, respectively (p  0.0049).
These randomized trials of LSCLC patients with good
prognostic factors suggest that small but statistically signifi-
cant survival gains can be achieved from chemotherapy
innovations for this group. However, there is a problem.
Unless profound differences exist in prognostic factors or
staging methods that make these patients incomparable to
other recently published LSCLC results, the median and
long-term survival outcomes of all these trials are clearly
inferior to what would be expected from early concurrent EP
and thoracic irradiation. With initial concurrent chemoradia-
tion, the median survival times exceed 20 months, 2-year
survival is over 40%, and actual 5-year survival rates of over
20% are fairly consistently reported.10,39,40 Concurrent ad-
ministration of full doses of EP and thoracic irradiation can
be accomplished with manageable toxicity without reduction
of either modality. However, when chemotherapy is manip-
ulated by dose intensification or addition of drugs that are less
compatible with thoracic irradiation, the fidelity of both
modalities of treatment is impaired by increased hematologic
and nonhematologic toxicity. As an example, a recently
reported Radiation Therapy Oncology Group phase II study41
that incorporated paclitaxel with EP and twice-daily thoracic
irradiation (45 Gy in 3 weeks) showed a favorable median
survival of 24.7 months and a 2-year survival rate of 54%.
Four- and 5-year survival was approximately 20%. Grade 3
and 4 esophagitis was 32% and 4%, respectively, and 6%
died as a result of toxicity. After due consideration, the
authors concluded that this three-drug protocol was unlikely
to improve the results in LSCLC compared to the standard EP
chemotherapy regimen and this line of investigation would be
pursued no further.
The demographic patterns of patients diagnosed with
LSCLC are not conducive to increasingly toxic combined-
modality protocols. Gaspar et al.42 examined a National
Cancer Data Base including four patient cohorts diagnosed
with LSCLC in 1985 (n  2123), 1990 (n  6279), 1995
(n  7815), and 2000 (n  2123). The proportion of patients
aged 70 years or older increased significantly over time, from
31.6% in 1985 to 44.9% in 2000 (p  0.001). Moreover,
SCLC patients are generally physiologically aged beyond
their chronologic age, at least in part because of heavy
smoking. This analysis identified the continued need for the
evaluation of new treatments in this group of patients, but
more aggressive chemotherapy in combined-modality proto-
cols is unlikely to enhance the therapeutic index.
COMBINED MODALITY THERAPY FOR LSCLC
Thirteen randomized studies, including 2140 patients,
have investigated the role of thoracic radiotherapy in LSCLC.
Two meta-analyses5,43 have been published that examine
these trials. Both show a modest improvement in survival
rates in those patients given thoracic radiotherapy in addition
to chemotherapy. Survival benefit becomes evident at ap-
proximately 15 months after the start of treatment and persists
beyond 5 years. At 3 years, 8.9% of the chemotherapy-only
group is alive, compared with 14.3% of the combined-
modality group. The relative risk of death in the combined-
modality group as compared with the chemotherapy group
was 0.86 (95% confidence interval [CI], 0.78–0.95; p 
0.001), corresponding to a 14% reduction in the mortality
rate. The analysis of local control showed a 2-year local
failure rate of 23% for irradiated patients versus 48% for
nonirradiated patients (p  0.0001). These benefits were
obtained at the cost of an increase in treatment-related deaths
of 1%.
The meta-analyses5,43 have been a valuable addition to
the oncology literature, and the principal conclusion that
chemotherapy combined with thoracic irradiation is superior
to chemotherapy alone is undoubtedly correct. However, the
meta-analyses underestimate the absolute long-term survival
contribution of state-of-the-art integrated chemoradiation.
Most studies in the meta-analyses commenced before 1981
and none delivered cisplatin and etoposide either as initial
treatment or concurrently with thoracic irradiation. The rela-
tive risk of death method rather than the proportion of
long-term survivors measured outcome. The survival curve is
initially better for chemotherapy alone, and at approximately
1 year, the curves cross to show a clear benefit of combined-
modality therapy on long-term survival. Chemotherapy pre-
scriptions from a previous era that administer concurrent
chemoradiation with cyclophosphamide, doxorubicin, and
nitrosoureas are associated with problematic hematologic and
nonhematologic toxicity. Reliable delivery of both chemo-
therapy and radiotherapy is uncertain. The negative impact of
chemoradiation using incompatible chemotherapy regimens
can be seen in two subgroups reported in the meta-analysis of
Pignon.5
Subgroup analysis on the basis of age indicated that the
benefit from radiotherapy on mortality was greatest for pa-
tients younger than 55 years of age (p  0.01). The relative
risk of death in favor of combined-modality therapy was 0.72
(95% CI, 0.56–0.93) for patients younger than 55 years and
1.07 (95% CI, 0.70–1.64) for patients older than 70 years.
This adverse effect of age on the benefit of combined-
modality therapy has been contradicted by two recent stud-
ies44,45 that have examined treatment effects in older (70
years) versus younger (70 years) patients in studies that
administered early EP with thoracic irradiation. The two
groups were similar for baseline patient characteristics, treat-
ment field sizes, toxicity, response rates, and overall survival.
These analyses conclude that age does not appear to have an
impact on the delivery, tolerance, or efficacy of radiotherapy,
when used with platinum/etoposide, for patients with
LSCLC. A plausible explanation of the discrepancy would be
that toxicity of concurrent chemoradiation as used in the trials
examined in the meta-analysis had a disproportionate effect
on elderly patients. Clearly, fit elderly patients should not be
denied the benefit from chemoradiation for LSCLC based on
the meta-analysis.5
The same meta-analysis5 examined the question of the
timing of thoracic irradiation (sequential, alternation, and
concurrent), and no statistically significant differences were
found among the various treatment schedules. However, three
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of the four trials that showed a significant survival advantage
for combined-modality therapy used a concurrent or alternat-
ing scheme, whereas seven of the nine trials that did not
demonstrate a survival advantage used a sequential plan.
Comparisons between sequential and concurrent therapy de-
pend on compatibility of chemotherapy and radiotherapy; in
fact, the alternating methodology was used as a way to get
around the excess toxicity of concurrent therapy with an
anthracycline. The use of anthracyclines and alternating ther-
apy has faded into the past but rises with each evidence-based
assessment and review of these studies. The survival advan-
tage of thoracic irradiation becomes important at 2 to 5 years
in LSCLC when the proportion of cured patients becomes
manifest.10
SEQUENCING AND TIMING OF THORACIC
RADIOTHERAPY
Although investigation of thoracic irradiation timing is
reported in seven randomized trials39,40,46–50 of varying struc-
ture, size, and vintage, sequence and timing continue to
generate controversy. Recently, a meta-analysis performed
according to the Cochrane Collaboration Guidelines exam-
ined randomized controlled clinical trials comparing different
timing of chest radiotherapy in patients with LSCLC.51 Early
chest irradiation was defined as beginning within 30 days
after the start of chemotherapy. Seven randomized trials were
eligible.39,40,46–50 A weighted estimate of the typical treat-
ment effect across studies was computed for 2-year survival
data and for the 5-year survival data, local control, and
toxicities. The odds ratio (OR) was used as the effect mea-
sure. Taking all seven studies into account, the overall sur-
vival at 2 years or at 5 years was not significantly different
between early or late chest radiotherapy (OR for 2 years,
0.84; 95% CI, 0.56–1.28; OR at 5 years, 0.80; 95% CI,
0.47–1.38). When the one trial that delivered nonplatinum
chemotherapy concurrently with chest radiation46 was ex-
cluded, the OR was significantly in favor of early chest
radiotherapy at 5 years (OR, 0.64; 95% CI, 0.44–0.92; p 
0.02). Considering studies with an overall treatment time of
chest irradiation of less than 30 days,39,40,47,49,50 the 5-year
survival was even better (OR, 0.56; 95% CI, 0.37–0.85; p 
0.006). As expected, esophageal and pulmonary toxicity was
worse with initial concurrent chemoradiation, but severe
leukopenia was more frequent in patients receiving late chest
radiotherapy (p  0.0004).
Although a conclusion in favor of early concurrent
chemoradiation for LSCLC is not definitive, analysis of
relevant subsets of the data is rational. Exclusion of nonplati-
num chemotherapy is supported by a meta-analysis showing
superiority of SCLC regimens containing cisplatin52 and a
conclusive phase III trial showing better survival of the EP
regimen compared with a cyclophosphamide/anthracycline-
based regimen.35 Early thoracic irradiation cannot be ex-
pected to perform well unless it is coupled with a chemother-
apy regimen compatible with concurrent radiotherapy and
efficacious enough to improve control of micrometastases
outside the thoracic irradiation volume. Parenthetically, the
odds ratios adduced in favor of early concurrent thoracic
irradiation versus delayed thoracic irradiation (0.80, 0.64, and
0.56) in the meta-analysis by Pijls et al.51 are more favorable
than the OR of 0.86 in favor of combined-modality therapy
versus chemotherapy alone (0.86).5
Another factor that influenced the less than robust
statistics of the meta-analysis on the timing of thoracic
irradiation is that the prognostic factors of the patients in the
trials appear different. If a poor prognosis LSCLC population
(as evidenced by a short median survival) is studied, the
proportion of patients who can have their prognosis improved
by better integration of chemoradiation will be low and the
benefit of early thoracic irradiation timing will be diluted by
a majority of incurable cases. That the study populations in
the Perry et al.,46 Work et al.,48 and James et al.50 trials, which
failed to show superiority of early chemoradiation, contained
more patients with a poorer prognosis is strongly suggested
by the short median survival times reported. The average
median survival of all patients (both arms) in these trials was
13.75 months for the Perry et al. trial, 11.25 months for the
Work et al. trial, and 14.3 months for the James et al. study.
In the trials that support early concurrent chemoradiation, the
average median survival of all trial patients was 18.6 months
for the Murray et al. study,53 23.5 months for the Takada et
al. trial,39 and 30 months for the Jeremic et al. trial.47 These
are rather large differences. Selection of patients for com-
bined-modality trials of stage III NSCLC requires that the
patient population be carefully staged and has favorable
prognostic factors. Similarly, in LSCLC, patients that benefit
from early concurrent chemoradiation are those with good
prognostic factors and a reasonable chance of being cured.
THE CHEMORADIATION PACKAGE AND SER
The concept of the “chemoradiation package” has been
discussed by Peters and Withers54 with regard to the treat-
ment of head and neck cancers. Most sequential combined-
modality protocols emerged as pragmatic grafting of chemo-
therapy onto a course of radiotherapy. The failure of
induction chemotherapy to improve results in the combined-
modality treatment of head and neck cancer55 can be ex-
plained by the hypothesis that the cell kill produced by
induction chemotherapy is offset by tumor cell regeneration
occurring during the prolonged overall course of treatment.
The duration of the chemoradiation package for
LSCLC may be defined as the time elapsed from the first
therapeutic intervention until the completion of the radiother-
apy treatment. The use of this definition does not presume
that additional chemotherapy cycles after completion of ra-
diotherapy are unimportant but that the rapid tumor destruc-
tion caused by combined-modality therapy is crucial and
markedly influences the probability that treatment will even-
tually eliminate the last tumor clonogen. That initial concur-
rent chemoradiation is the most efficient way to rapidly
destroy cancer cells is self-evident. Based on data from in
vitro assays of radiosensitivity of human small cell lung
cancer lines,56 numerically, more cancer clonogens are elim-
inated locally by the first 2-Gy fraction (SF2) than by the
entire remainder of the radiotherapy course. When initial
concurrent systemic chemotherapy is added to the radiother-
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apy effect, inhibition of tumor repopulation and metastatic
events by rapid tumor destruction will be greater than delay-
ing radiotherapy during protracted induction chemotherapy.
The theoretical basis of the superiority of initial chemoradia-
tion is discussed in detail elsewhere.57
This concept has recently been statistically evaluated
by De Ruysscher et al.58 from The Netherlands. The hypoth-
esis was that the overall treatment time available for accel-
erated proliferation of tumor cells could be a major determi-
nant of tumor outcome in LSCLC. They performed a
systematic overview and identified six published phase III
trials10,39,40,47,48,59 combining chest irradiation and platinum-
based chemotherapy in the primary management of LSCLC
and reporting 5-year survival. The following parameters and
their influence on local tumor control, survival, esophagitis,
and pneumonitis were analyzed: the total radiotherapy dose,
the overall treatment time of chest radiotherapy, the day of
the start of radiotherapy as an indicator of early versus late
radiation, the SER (start of any treatment till the end of
radiotherapy), concurrent versus sequential radiotherapy and
chemotherapy, the study period measured by the year the trial
was initiated, and the Equivalent Radiation Dose in 2-Gy
fractions, corrected for the overall treatment time of chest
radiotherapy (EQD2, T). The definition of SER and the
chemoradiation package are the same.
Using meta-analysis methodology, the SER was the
most important predictor of outcome. There was a signifi-
cantly higher 5-year survival in the shorter SER arms (OR,
0.60; 95% CI, 0.45–0.80; p  0.0006), which was more than
20% when the SER was less than 30 days. Although no
significant relation between the SER and local tumor control
was found (OR, 0.73; 95% CI, 0.46–1.14; p  0.16), local
tumor control was higher with increasing EQD2, T radiation
doses (p  0.02). This suggests that for local tumor control,
both time and radiation dose factors are important. A lower
SER was associated with a higher incidence of severe esoph-
agitis (OR, 0.47; 95% CI, 0.33–0.66; p  0001). The SER
was not statistically associated with pneumonitis (too few
events), severe leukopenia, or thrombocytopenia.
The authors concluded that a short SER (30 days)
results in improved survival for LSCLC patients. This novel
parameter, taking into account accelerated proliferation of
tumor during both radiotherapy and chemotherapy, may fa-
cilitate a more rational design of combined-modality treat-
ment in rapidly proliferating tumors.
RADIOTHERAPY TARGET VOLUME
Selection of a target to treat has evolved because of
computed tomography and treatment planning systems that
allow more accurate definition of structures that warrant
treatment from anatomy that causes toxicity. Global medias-
tinal and supraclavicular irradiation dominated thoracic ra-
diotherapy ports through the trials of the 1980s, including the
Intergroup Trial,10 where regional nodal irradiation encom-
passed the entire mediastinum. Relapse patterns rarely report
regional nodal failure as the first or ultimate site of relapse,
and this is especially true of supraclavicular nodal regions. As
with other occult positive disease sites, they can be managed
with systemic chemotherapy; treating uninvolved nodes with
radiotherapy may not be necessary, and exposing radiograph-
ically normal nodal stations to radiation beams may add to
toxicity. Diminishing mediastinal irradiation only to areas of
bulky nodes reduces exposure to the esophagus, lung, and
other sensitive normal tissues and reduces esophagitis and
pneumonitis.
Target size can be challenging with initial concurrent
therapy if the initial bulk is too large for a reasonable
radiotherapy port. This fact may influence the sequence of
therapy. A cycle or two of chemotherapy may reduce volume
sufficiently to more facilely apply radiation beams without
excessive irradiation to the lungs. The target can then become
the residual mass after reduction attributable to the chemo-
therapy. Data supporting this are limited, but an analysis from
the Mayo Clinic60 shows support for the tactic of targeting
postchemotherapy residual or at least no clear hazard by not
encompassing the initial bulk. This issue has not drawn
sufficient attention to construct a clinical trial to test volume-
related issues in a prospective trial.
Targeting and treating only nodal structures that mea-
sure 1 cm or larger on computed tomographic scan, clinically
palpable nodes in the supraclavicular fossa and disease found
by bronchoscopy constitute an appropriate target. Elective
treatment of uninvolved nodes does not have a good ratio-
nale, and the risk of normal tissue exposure with toxicity of
esophagitis and reduction in lung function militates strongly
against expansive volumes.
RADIOTHERAPY DOSE, TIME, AND
FRACTIONATION
The duration of overlapping chemotherapy and thoracic
radiotherapy may influence tolerability, survival, and toxic-
ity. The 1980s issue for thoracic radiotherapy was whether it
was needed at all, and the responsiveness of SCLC to either
radiotherapy or chemotherapy was so great that higher doses
were not contemplated. Doses commonly recommended were
in the range of 40 to 50 Gy. Because of concern for spinal
cord tolerance, simple techniques were used to deliver spinal
cord tolerance such as a posterior shield. The fact that the
spinal cord shield also blocked tumor centrally was consid-
ered a necessary problem. Since that time, treatment planning
techniques allow delivery of doses to the target defined by
radiation oncologists without concern for spinal cord toler-
ance, and toxicity to the lung and esophagus are more
practical concerns. Modern planning allows delivery of doses
higher than ever considered 25 years ago either by once- or
twice-daily treatment.
According to the evidence, the standard dose and treat-
ment for LSCLC is 45 Gy delivered in 3 weeks in 30 fractions
of 1.5 Gy, administered concurrently with cisplatin plus
etoposide.10 The North Central Cancer Treatment Group
Study,61 which also used a twice-daily treatment arm, failed
to show differences between the twice-daily treatment and
once-daily treatment. However, both arms had delayed initi-
ation of chemoradiotherapy after induction chemotherapy,
and the duration of radiotherapy was not different despite a
twice-daily scheme. The trial intentionally put a treatment
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interruption in midcourse on the twice-daily arm, but that
resulted in a reduction of toxicity. There was no significant
difference in survival. The interruption muted any effect of
twice-daily treatment. Although some cast doubt that twice-
daily treatment is superior because of this trial, the interrup-
tion and protraction of treatment diminished the intensity of
the radiotherapy. Thus, the twice-daily treatment with too
much time off over too long of a period blunts esophagitis,
but blunts any effect on survival as well. In Canada, 40 Gy in
3 weeks is still widely used.40 We really do not know that
longer treatments or higher doses are better for local control
or survival, but we are now able to deliver doses up to 70 Gy
in 7 weeks62 without a clear signal that higher doses are
superior. The Massachusetts General Hospital group63 has
consistently endorsed a policy of higher doses of once-daily
treatment and have slowly escalated the dose in successive
cohorts of patients to 70 Gy. Survival plots of patients treated
at higher doses show no inferiority and possibly a slight
benefit for protracted high-dose treatment. Both Cancer and
Leukemia Group B and Massachusetts General Hospital data
sets use induction chemotherapy and postchemotherapy tar-
get volumes. American cooperative groups have escalated
LSCLC thoracic radiotherapy doses to doses of 61 to 63 Gy,
paralleling doses used for stage III NSCLC. However, none
of these doses appears superior to 40 to 45 Gy in 3 weeks, and
lengthy high-dose treatments over 6 to 7 weeks are associated
with a long SER. In addition, protracted thoracic irradiation
overlaps with more chemotherapy cycles, leading to more
dose reductions and delays. There is no evidence from con-
trolled trials that demonstrates benefit to higher dose thoracic
irradiation and no such study has been approved.
PROPHYLACTIC CRANIAL IRRADIATION
Patients with cancer control outside the brain have a
60% actuarial risk of developing brain metastases within 2 to
3 years after starting treatment. In a meta-analysis of seven
randomized trials evaluating the value of prophylactic cranial
irradiation (PCI), the risk of developing central nervous
system metastases was reduced by more than 50%.64 In
addition, 3-year overall survival of complete responders (pre-
dominately LSCLC) was 20.7% with PCI versus 15.3% in the
control group.
The selection of an optimal dose for PCI that would
lead to further decreases in brain metastasis incidence with
minimal toxicity is the subject of an ongoing international
trial addressing the question of the optimal PCI dose for the
prevention of metastases. A standard dose of 25 Gy in 10
fractions is being compared with 36 Gy in 18 fractions or 36
Gy in 24 twice-daily fractions. PCI should not be given with
systemic chemotherapy because of increased toxicity.65
CONCLUSION
Because of the systemic nature of SCLC, the opportu-
nity for demonstrating treatment improvement would appear
to be greatest for chemotherapy, where there is a large array
of drug permutations and dosing variations. In addition, the
entire patient population could potentially benefit from a bona
fide advance in systemic treatment. For ESCLC, a number of
chemotherapy regimens have been demonstrated to be equiv-
alent to the cisplatin plus etoposide combination for ESCLC.
However, it has not been possible to unequivocally show that
any chemotherapy regimen is superior to four cycles of EP. In
the LSCLC patient population, the EP regimen is clearly
superior to cyclophosphamide plus anthracycline regimens.
Some evidence exists that incremental survival gains may be
seen when dose-intensive or more complex regimens are
administered before delayed thoracic irradiation. However,
the best reported results for LSCLC are achieved with initial
concurrent EP chemotherapy and thoracic irradiation. More
intensive protocols or regimens that add another chemother-
apeutic agent to the EP motif have not prospered in investi-
gations of LSCLC because of safety concerns and fidelity of
chemotherapy and radiotherapy delivery.
The frustration associated with the over 25-year tenure
of cisplatin plus etoposide as standard therapy for both
LSCLC and ESCLC is mitigated by favorable economic
factors. The drug acquisition cost of etoposide and cisplatin
for a 1.75-m2 patient at the British Columbia Cancer Agency
is US$60 per cycle (US$240 for the entire four-cycle pre-
scription). This represents one of the best bargains for state-
of-the-art chemotherapy in cancer medicine. When one con-
siders the fact that the same model of treatment has achieved
some of the best reported results for locally advanced
NSCLC,11 the importance of modest drug costs for treatment
with curative intent of a common disease worldwide should
not be understated. Lung cancer is a global pandemic, and the
International Association for the Study of Lung Cancer has a
responsibility to recognize and endorse cost-effective ther-
apy.
Although chemotherapy advances have been disap-
pointing in SCLC, innovations of radiotherapy from LSCLC
articles published during the 1990s demonstrated that a num-
ber of radiotherapy interventions had significant survival
benefits. These radiotherapy interventions include addition of
thoracic irradiation to chemotherapy, early delivery of tho-
racic irradiation concurrently with chemotherapy, more in-
tense thoracic irradiation, and prophylactic cranial irradiation
Over the past 20 years, there has been extensive inves-
tigation combining definitive radiotherapy and systemic che-
motherapy with curative intent for a wide variety of locally
advanced neoplasms. Induction or neoadjuvant chemotherapy
has been popular logistically, but when evidence from ran-
domized trials is examined, the model of treatment that has
consistently generated improved survival for brain cancer,
head and neck cancer, anal cancer, cervical cancer, NSCLC,
and LSCLC is early concurrent chemoradiation. As there are
major unanswered questions in the management of LSCLC,
the rational design of combined-modality protocols and clin-
ical trials incorporating new treatments must respect basic
radiobiological principles.
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